MedTrace Logo

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

NCT04892953 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-02-19

No results posted yet for this study

Summary

This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after chemoradiation and anti-PD-l1 therapy. Local consolidative therapy, such as surgery and/or radiation, after initial treatment may kill any remaining tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving local consolidative therapy and durvalumab may help to control the disease.

Conditions

  • Stage III Lung Cancer AJCC v8
  • Stage III Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIB Lung Cancer AJCC v8
  • Stage IIIB Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIC Lung Cancer AJCC v8

Interventions

DRUG

Carboplatin

Given IV

BIOLOGICAL

Durvalumab

Given IV

DRUG

Gemcitabine

Given IV

PROCEDURE

Local Consolidation Therapy

Undergo LCT

DRUG

Nab-paclitaxel

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Pemetrexed

Given IV

OTHER

Quality-of-Life Assessment

Complete questionnaire

OTHER

Questionnaire Administration

Complete questionnaire

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Joe Y Chang, MD,MS,PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04892953 on ClinicalTrials.gov